about
The development of immunoconjugates for targeted cancer therapyA current perspective on applications of macrocyclic-peptide-based high-affinity ligandsSite-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and GlycansTargeting FcRn for the modulation of antibody dynamicsThe neonatal Fc receptor, FcRn, as a target for drug delivery and therapyMolecular Imaging of Pancreatic Cancer with Antibodies.Nanobody: the "magic bullet" for molecular imaging?Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors.Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.CF750-A33scFv-Fc-Based Optical Imaging of Subcutaneous and Orthotopic Xenografts of GPA33-Positive Colorectal Cancer in Mice.Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment.Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.Synthesis and pre-clinical evaluation of an (18)F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancerPharmacokinetic properties of IgG and various Fc fusion proteins in mice.Antibody-based imaging strategies for cancer.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.In vivo imaging with antibodies and engineered fragments.Epidermal growth factor receptor imaging in human head and neck cancer xenografts.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.New prospects for PET in prostate cancer imaging: a physicist's viewpoint.ImmunoPET Imaging of αvβ6 Expression Using an Engineered Anti-αvβ6 Cys-diabody Site-Specifically Radiolabeled with Cu-64: Considerations for Optimal Imaging with Antibody Fragments.NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.Advances in PET Detection of the Antitumor T Cell Response.68Ga-labeled cyclic NGR peptide for microPET imaging of CD13 receptor expression.Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions.Immune Modulation Therapy and Imaging: Workshop Report.First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging.Improving theranostics in pancreatic cancer.Chemical biology: Protein modification in a trice.Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysis.Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
P2860
Q27021990-4969BDB5-0B6B-4AA5-A8AA-B6ED6EA339D1Q28072407-7060966F-65A3-497A-B32A-E572C1FC5BC1Q28078378-7FD4244D-752E-45B2-BDD6-7DA99688BEE4Q28080589-5C1E197F-DC6D-41B5-A281-F634D3B0F177Q28257521-DEF019C8-EAF7-4151-94C7-80D4223B4C36Q30393523-F2BF86EE-8597-4541-B7B1-CCE18DE381FEQ30442626-56F748AB-B658-416D-A038-47B4FE0CD0AFQ33597766-01581454-E870-4996-B405-0A613CAFF8B2Q34313174-0EA158B1-5B4F-49D1-AEE8-A176C593A991Q35602239-E8D8D9A6-D5D3-465C-9253-4A5184A4F04EQ35680685-B7082FAF-05B3-413E-B371-C50004D2F725Q36418274-59641C3E-BA28-4CF5-AA6E-0201463B3CF6Q36437102-A0F6EDA4-4932-4539-BB8C-7ADC7A8AA8F1Q36724890-F9B4BD8E-8741-4DB8-85F3-D7D34FCBE77BQ36877472-C690D488-EA90-472F-B0C6-5A57EF742011Q37136748-4DF9DD5C-F82D-4CDD-84FD-AE2BB6B8A0CFQ37138252-E1E02D97-D4D4-4C36-B6C6-7EEEF7FA2461Q38218986-E63E9D9E-5761-4814-A22C-9EE7C8066089Q38289992-D61574C8-599B-4345-A469-1F321B09339AQ38454458-0E888302-6806-42B3-9DED-5D1381528B98Q38561772-7BA1ADAF-6737-47F7-89FB-A81CADF55CEAQ38610286-D88FC283-E607-4027-9F26-BD89040AE301Q38616392-1AC9701C-3C2C-4094-BC7D-E734261ABC4EQ38666311-E6746AC2-A2B4-4297-869D-ED66A05D58C6Q38767020-E718F022-69EB-455A-B6BF-540219DAC901Q38846891-83750282-ECA6-4326-85F9-E986C062FF78Q38968218-D642E9F7-CAA8-4D93-B230-07D68025B7F2Q39083974-FB56819D-BDB4-4EEE-92B2-C036118D511BQ40089191-3909EA90-D412-4E14-AF19-5F4C4B8BCD0BQ40625131-0B801408-789B-43D9-B8E2-02D233B522D2Q41455532-93F1D5D1-384C-47E1-A653-926463B2847AQ46466095-4A8BDC24-B54F-4D30-9E6B-50A092378048Q46705433-551F1833-2C14-45A2-97DA-2B6F3C779B5AQ48131836-74D9A1B7-1CDF-4275-9F68-EAB3F359E26EQ48192595-9E28D9D6-708D-4223-9BF0-9CD3C66FEC5EQ48227716-8B955191-4E0B-4362-A2D4-6EED507976A9Q51740406-96AD8532-5738-4FBB-8541-90A6206258D4Q55257427-E8E3AB50-6B14-483D-999F-AB06E0666AAD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Engineered antibodies for molecular imaging of cancer.
@en
type
label
Engineered antibodies for molecular imaging of cancer.
@en
prefLabel
Engineered antibodies for molecular imaging of cancer.
@en
P2860
P1433
P1476
Engineered antibodies for molecular imaging of cancer.
@en
P2093
P2860
P304
P356
10.1016/J.YMETH.2013.09.015
P577
2013-10-01T00:00:00Z